BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 23780998)

  • 1. Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma.
    Rodríguez-Antona C; Muñoz-Repeto I; Inglada-Pérez L; de Cubas AA; Mancikova V; Cañamero M; Maliszewska A; Gómez A; Letón R; Leandro-García LJ; Comino-Méndez I; Sanchez L; Alvarez-Escolá C; Aller J; Cascón A; Robledo M
    Endocr Relat Cancer; 2013 Aug; 20(4):611-9. PubMed ID: 23780998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VEGF, VEGFR3, and PDGFRB protein expression is influenced by RAS mutations in medullary thyroid carcinoma.
    Mancikova V; Inglada-Pérez L; Curras-Freixes M; de Cubas AA; Gómez Á; Letón R; Kersten I; Leandro-García LJ; Comino-Méndez I; Apellaniz-Ruiz M; Sánchez L; Cascón A; Sastre-Marcos J; García JF; Rodríguez-Antona C; Robledo M
    Thyroid; 2014 Aug; 24(8):1251-5. PubMed ID: 24754736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis.
    Rodríguez-Antona C; Pallares J; Montero-Conde C; Inglada-Pérez L; Castelblanco E; Landa I; Leskelä S; Leandro-García LJ; López-Jiménez E; Letón R; Cascón A; Lerma E; Martin MC; Carralero MC; Mauricio D; Cigudosa JC; Matias-Guiu X; Robledo M
    Endocr Relat Cancer; 2010 Mar; 17(1):7-16. PubMed ID: 19776290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
    Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
    Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
    Elisei R; Cosci B; Romei C; Bottici V; Renzini G; Molinaro E; Agate L; Vivaldi A; Faviana P; Basolo F; Miccoli P; Berti P; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2008 Mar; 93(3):682-7. PubMed ID: 18073307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways.
    Ameur N; Lacroix L; Roucan S; Roux V; Broutin S; Talbot M; Dupuy C; Caillou B; Schlumberger M; Bidart JM
    Endocr Relat Cancer; 2009 Dec; 16(4):1261-72. PubMed ID: 19675075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular analysis of the RET proto-oncogene key exons in patients with medullary thyroid carcinoma: a comprehensive study of the Iranian population.
    Alvandi E; Akrami SM; Chiani M; Hedayati M; Nayer BN; Tehrani MR; Nakhjavani M; Pedram M
    Thyroid; 2011 Apr; 21(4):373-82. PubMed ID: 21309721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of Tenascin C, EGFR, E-Cadherin, and TTF-1 in Medullary Thyroid Carcinoma and the Correlation with RET Mutation Status.
    Steiner F; Hauser-Kronberger C; Rendl G; Rodrigues M; Pirich C
    Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27409604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single nucleotide polymorphisms act as modifiers and correlate with the development of medullary and simultaneous medullary/papillary thyroid carcinomas in 2 large, non-related families with the RET V804M proto-oncogene mutation.
    Shifrin AL; Ogilvie JB; Stang MT; Fay AM; Kuo YH; Matulewicz T; Xenachis CZ; Vernick JJ
    Surgery; 2010 Dec; 148(6):1274-80; discussion 1280-1. PubMed ID: 21134561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification.
    Mian C; Pennelli G; Barollo S; Cavedon E; Nacamulli D; Vianello F; Negro I; Pozza G; Boschin IM; Pelizzo MR; Rugge M; Mantero F; Girelli ME; Opocher G
    Eur J Endocrinol; 2011 Jun; 164(6):971-6. PubMed ID: 21422198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High prevalence of exon 8 G533C mutation in apparently sporadic medullary thyroid carcinoma in Greece.
    Sarika HL; Papathoma A; Garofalaki M; Vasileiou V; Vlassopoulou B; Anastasiou E; Alevizaki M
    Clin Endocrinol (Oxf); 2012 Dec; 77(6):857-62. PubMed ID: 22676047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma.
    Rapa I; Saggiorato E; Giachino D; Palestini N; Orlandi F; Papotti M; Volante M
    J Clin Endocrinol Metab; 2011 Jul; 96(7):2146-53. PubMed ID: 21543427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.
    Kushchayeva Y; Jensen K; Recupero A; Costello J; Patel A; Klubo-Gwiezdzinska J; Boyle L; Burman K; Vasko V
    J Clin Endocrinol Metab; 2014 May; 99(5):E734-45. PubMed ID: 24483157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline RET mutations in exons 10 and 11: an Iranian survey of 57 medullary thyroid carcinoma cases.
    Hedayati M; Nabipour I; Rezaei-Ghaleh N; Azizi F
    Med J Malaysia; 2006 Dec; 61(5):564-9. PubMed ID: 17623957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development.
    van Veelen W; van Gasteren CJ; Acton DS; Franklin DS; Berger R; Lips CJ; Höppener JW
    Cancer Res; 2008 Mar; 68(5):1329-37. PubMed ID: 18316595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical diagnosis and treatment of familial medullary thyroid carcinoma caused by a p.C618Y RET proto-oncogene mutation in a Chinese pedigree].
    Zhao JQ; Guo L; Qi XP; Chen ZG; Wang KJ; Lou JL; Yu XH; Cheng J; Jin HY; Li XL; Ying RB; Zhang XN
    Zhonghua Yi Xue Za Zhi; 2013 Feb; 93(6):440-4. PubMed ID: 23660264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre.
    Bugalho MJ; Domingues R; Santos JR; Catarino AL; Sobrinho L
    Surgery; 2007 Jan; 141(1):90-5. PubMed ID: 17188172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas.
    Dvorakova S; Vaclavikova E; Sykorova V; Vcelak J; Novak Z; Duskova J; Ryska A; Laco J; Cap J; Kodetova D; Kodet R; Krskova L; Vlcek P; Astl J; Vesely D; Bendlova B
    Mol Cell Endocrinol; 2008 Mar; 284(1-2):21-7. PubMed ID: 18282654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis.
    Johanson V; Ahlman H; Bernhardt P; Jansson S; Kölby L; Persson F; Stenman G; Swärd C; Wängberg B; Stridsberg M; Nilsson O
    Endocr Relat Cancer; 2007 Jun; 14(2):433-44. PubMed ID: 17639056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.